Suchergebnisse - "Engel-Riedel, Walburga"

PubPharm (61)

1

Evolutionary trajectories of small cell lung cancer under therapy

enthalten in: Nature | 2024

von George, J. | Maas, L. | Abedpour, N. | +64

2

Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma : Subgroup Analysis of the UNFOLDER Trial

enthalten in: HemaSphere | 2023

von Held, G. | Thurner, L. | Poeschel, V. | +30

3

Radiation and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma : subgroup analysis of the UNFOLDER trial

enthalten in: HemaSphere | July 2023

von Held, G. | Thurner, L. | Poeschel, V. | +30

4

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY) : a randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2019

von Nakagawa, K. | Garon, E. | Seto, T. | +118

CommentIn: Lancet Oncol. 2019 Dec;20(12):1617-1618. - PMID 31591061

5

Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer

enthalten in: JCO precision oncology | 2019

von Michels, S. | Heydt, C. | van Veggel, B. | +40

6

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer

enthalten in: The New England journal of medicine | 2018

von Paz-Ares, L. | Luft, A. | Vicente, D. | +120

CommentIn: Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S349-S351. - PMID 30705852

7

Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

enthalten in: Nature communications | 2018

von Fassunke, J. | Müller, F. | Keul, M. | +36

8

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

enthalten in: The New England journal of medicine | 2018

von Gandhi, L. | Rodríguez-Abreu, D. | Gadgeel, S. | +127

CommentIn: Cancer Discov. 2018 Jun;8(6):OF7. - PMID 29666060

9

Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2018

von Christopoulos, P. | Schneider, M. | Bozorgmehr, F. | +12

10

A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer

enthalten in: Journal for immunotherapy of cancer | 2018

von Engel-Riedel, W. | Lowe, J. | Mattson, P. | +8

1
2
3
4
5
6
7
Nächster »
[7]